Suven Life Sciences Ltd Financials
Company Logo

Suven Life Sciences Ltd Financial Statement

Suven Life Sciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue6.61
Operating Expense16.21
Net Profit-11.07
Net Profit Margin-167.47
Earning Per Share-0.51
EBIDTA-9.59
Effective Tax RateTBA
Invest in Suven Life Sciences Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Suven Life Sciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual11.69
Operating Expenses Annual42.63
Operating Profit Annual-2.35
Interest Annual0.16
Depreciation6.47
Net Profit Annual-8.01
Tax Annual-1.00

Suven Life Sciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning26.70
Cash Flow from Operations-20.56
Cash Flow from Investing-0.68
Cash Flow from Financing-1.05
Cash Flow at the End4.40

Suven Life Sciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)-122.16
PBIT Margin (%)-177.76
PBT Margin (%)562.87
Net PROFIT Margin (%)-68.52
Return On Networth / Equity (%)-2.36
Return On Networth /Employed (%)-2.44
Return On Assets (%)-0.69
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)0.01

Suven Life Sciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual28.21
Total Current Assets Annual246.14
Non Current Assets Annual605.34
Total Shareholders Funds Annual845.38
Total Assets Annual851.48

Suven Life Sciences Ltd Earning Calls

EPS (INR)

Expected

0.00

Reported

-2.27

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 23, 2024, Suven Life Sciences Ltd has a market capitalization of 2,174.19 Cr. Value Research classifies it as a Mid-Cap company.
Yes, Suven Life Sciences Ltd is debt-free with a debt-to-equity ratio of 0.00.
In FY 2023 , Suven Life Sciences Ltd recorded a total revenue of approximately 11.69 Cr marking a significant milestone in the company's financial performance.
Suven Life Sciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and -0.0% annually, respectively..
Suven Life Sciences Ltd's current PE ratio is -271.43.
Suven Life Sciences Ltd's ROCE averaged -4.4% from the FY ending March 2022 to 2024, with a median of -3.0%. It peaked at -1.9% in March 2024, reflecting strong capital efficiency over the period..
Suven Life Sciences Ltd's latest EBIT is Rs. -8.85 Cr, surpassing the average EBIT of Rs. -21.47 Cr over the 5 years..